Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Argus Health
Harvard Business School
Dow
Farmers Insurance
McKinsey
Julphar
US Army
Covington
Cantor Fitzgerald

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,699,492

« Back to Dashboard

Summary for Patent: 6,699,492
Title: Quinolone carboxylic acid compositions and related methods of treatment
Abstract:The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.
Inventor(s): Roy; Samir (San Ramon, CA), Chandrasekaran; Santosh Kumar (Moraga, CA), Imamori; Katsumi (Chiba, JP), Asaoka; Takemitsu (Chiba, JP), Shibata; Akihiro (Chiba, JP), Takahashi; Masami (Tokyo, JP), Bowman; Lyle M. (Pleasanton, CA)
Assignee: InSite Vision Incorporated (Alameda, CA) SSP Co., Ltd. (Tokyo, JP)
Application Number:10/126,513
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Delivery;

Drugs Protected by US Patent 6,699,492

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bausch And Lomb BESIVANCE besifloxacin hydrochloride SUSPENSION/DROPS;OPHTHALMIC 022308-001 May 28, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y METHOD OF TREATING OCULAR BACTERIAL INFECTIONS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,699,492

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,239,113 Topical treatment or prevention of ocular infections ➤ Try a Free Trial
7,056,893 Topical treatment for prevention of ocular infections ➤ Try a Free Trial
7,732,415 Topical treatment or prevention of ocular infections ➤ Try a Free Trial
7,749,970 Topical treatment of prevention of ocular infections ➤ Try a Free Trial
6,569,443 Topical treatment or prevention of ocular infections ➤ Try a Free Trial
6,685,958 Quinolone carboxylic acid compositions and related methods of treatment ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,699,492

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 296093 ➤ Try a Free Trial
Australia 2002322002 ➤ Try a Free Trial
Australia 3920300 ➤ Try a Free Trial
Australia 772228 ➤ Try a Free Trial
Canada 2368637 ➤ Try a Free Trial
Canada 2445408 ➤ Try a Free Trial
Cyprus 1107259 ➤ Try a Free Trial
Germany 1165058 ➤ Try a Free Trial
Germany 60020351 ➤ Try a Free Trial
Denmark 1165058 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fuji
Argus Health
Cipla
Daiichi Sankyo
Fish and Richardson
Cerilliant
Teva
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot